BioSpace News Archive

Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), (“Alpha Tau” or the “Company”), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the Company’s Investigational Device Exemption (IDE) application to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using the Alpha DaRT.

Nanosonics, a leader in infection prevention solutions, announced that patients in North America have been protected from the risk of ultrasound probe cross-contamination in over 100 million trophon® high level disinfection procedures.

InformedDNA®, the nation’s leading applied genomics solutions organization, announced that Dr. Sobha Pisharody has joined the company in its newly created role of Chief Strategy and Product Officer.

Recordati Rare Diseases Inc. announced that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 – 14, 2022.

Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty acid synthase (FASN) inhibitors, announced today that it will present additional Phase 2 data on denifanstat (formerly TVB-2640) identifying a predictive ‘metabolic signature’ in nonalcoholic steatohepatitis (NASH) patients.

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro Invitational XII Conference today, June 8, 2022 at 4:30 p.m. EDT.

Hinge Health announced results of the first-ever study demonstrating the financial benefits of digital musculoskeletal care for the Medicare population.

Innova Medical Group, Inc., today announced it successfully earned its CE mark certification (certificate N° 39032) of the Innova SARS-CoV-2 Antigen Rapid Qualitative Self-Test through GMED LNE Group, a leading certification organization and a distinguished Notified Body of the European Commission covering a vast range of products covered under both Invitro Diagnostic and Medical Device Regulations.

Promontory Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, announced today the peer-reviewed publication of its first-in-human Phase 1 study of lead therapeutic candidate, PT-112 in the July 2022 issue of eClinicalMedicine, part of The Lancet’s Discovery Science.

Acutis Diagnostics, a New York State laboratory, is taking on urgent healthcare issues through advancing medical testing capabilities.